PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830) to determine…Read More
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b2 Randomized Trial of Doxorubicin LIXTEs Lead AntiCancer Compound LB100 in Advanced Soft Tissue Sarcomas
